Latest Intelligence on Pharmaceutical Contract Research Organizations in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: new MabThera data challenges anti-TNFs

New data from Roche's IMAGE study presented at the European League Against Rheumatism congress show that administering MabThera at first-line may significantly slow joint damage and improve clinical outcomes in patients with rheumatoid arthritis. However, Datamonitor does not predict that these data will change the current treatment paradigms, as touted by the investigators.

Published By Datamonitor
12 Jun 2009
CommentWire
CommentWire

Amarin: RNA therapy results announced to attract suitors

In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

APA meeting 2009: Shire to maintain market leading status in ADHD

At the American Psychiatric Association's annual meeting, British pharmaceutical firm Shire presented data on its diverse attention deficit hyperactivity disorder portfolio, covering three key products. Through continued astute portfolio management, Datamonitor forecasts Shire to remain the market leader with a 40% share of the ADHD sector by 2017.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: new schizophrenia products and depot formulations

The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: novel drugs face challenges in mature depression and bipolar markets

At the recent meeting of the American Psychiatric Association, Forest/Gedeon Richter and Lundbeck attracted attention following the presentation of positive data for two novel drugs in bipolar disorder and depression, respectively. Given that both these indications are highly competitive and genericized markets, the companies are already seeking to differentiate their respective products.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: clinical data support potential label expansions in GAD

In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.

Published By Datamonitor
29 May 2009
CommentWire
CommentWire

Genta: Genasense Phase III melanoma trial gets go-ahead

The independent Data Monitoring Board for AGENDA, a Phase III trial of Genta's Genasense in advanced melanoma, has announced that the study can continue to completion. Should Genasense enter the melanoma market - an indication which has been tainted with late-stage drug failures - Genta may finally reap the commercial benefits of its long-term investment in this troubled drug.

Published By Datamonitor
20 May 2009
CommentWire
CommentWire

Pfizer: breakthrough for neuroendocrine tumor therapy

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor
13 Mar 2009
CommentWire
CommentWire

GSK: renewing the HIV pipeline

GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK lost its position as market leader to Gilead in 2007. The new collaboration with Idenix will, however, help the company to maintain its share in the fiercely competitive HIV market.

Published By Datamonitor
09 Feb 2009
CommentWire
CommentWire

Genentech/Roche/Biogen Idec: Rituxan receives boost from leukemia data

Rituxan is the most successful targeted therapy drug to date, having long been established as a standard in non-Hodgkin's lymphoma treatment. Regulatory approval in chronic lymphocytic leukemia will further drive the drug's sales potential. However, sales growth may be hindered in some markets due to Rituxan's existing off-label use.

Published By Datamonitor
09 Dec 2008

« | 1 | 2 | 3 | 4 | » »|

No help is available.